India], March 11: Merck Foundation, the philanthropic arm of Merck KGaA Germany, together with First Ladies of Africa and ...
Phenom unveiled its 2025 Talent Experience awards winners — celebrating the extraordinary achievements by organizations, ...
Merck Foundation, the philanthropic arm of Merck KGaA Germany together with First Ladies of Africa who are also their Ambassadors, Ministries of Health, Education, Communication & Gender, mark ...
Merck’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development of ...
3d
Clinical Trials Arena on MSNMerck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
6d
MoneyWeek on MSNVertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...
Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq.
Market traders are also anticipating at least two more rate cuts by the end of 2025 to support the Canadian economy in the face of slower global growth and trade uncertainties. In the U.S., stocks ...
With the rising adoption of checkpoint inhibitors and combination therapies, BAVENCIO's market growth is driven by expanding indications and strategic partnerships. However, competition from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results